Clinical trial
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic…
NCT00030355 · National Cancer Institute (NCI), NIH · Withdrawn
Key facts
| NCT number | NCT00030355 |
|---|---|
| Title | Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia |
| Official title | A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | homoharringtonine, chemotherapy |
| Enrollment | 0 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: